<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405950</url>
  </required_header>
  <id_info>
    <org_study_id>AT10-ZC-08</org_study_id>
    <nct_id>NCT01405950</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy</brief_title>
  <official_title>Single-Dose, Phase 1b Study to Assess Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects With Mild to Moderate Spasticity Due to Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety
      and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in
      Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the study's progress after the amendment remained challenging with continued
      pre-screen failures noted in areas of Botox injection inclusion; family participation refusal
      / disinterest and gastric or jejunostomy tube placement. A third protocol amendment to
      improve enrollment was discussed with the Investigators who did not believe further amendment
      would overcome the barriers expressed by parents that would subject their children to an
      intense study time commitment without direct benefit. The investigative sites were notified
      that the study was closed to enrollment March 27, 2012.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why
    study stopped.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter AUC0-8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</measure>
    <time_frame>Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours</time_frame>
    <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</measure>
    <time_frame>Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours</time_frame>
    <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Spasticity Due to Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanaflex Capsules</intervention_name>
    <description>0.025 mg/kg</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <other_name>tizanidine HCI (hydrochloride)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanaflex Capsules</intervention_name>
    <description>0.05 mg/kg</description>
    <arm_group_label>Dose Level 2</arm_group_label>
    <other_name>tizanidine HCI (hydrochloride)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanaflex Capsules</intervention_name>
    <description>0.075 mg/kg</description>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>tizanidine HCI (hydrochloride)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanaflex Capsules</intervention_name>
    <description>0.1 mg/kg</description>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>tizanidine HCI (hydrochloride)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have clinically diagnosed spasticity resulting from cerebral palsy

          -  Have a motor disability resulting from a static, nonprogressive brain injury or
             malformation occurring prenatally or before the age of 2 years

          -  Have mild to moderate spasticity at screening

          -  Have a parent or legally accepted representative able to understand and comply with
             study requirements who voluntarily provides informed consent and agrees to be
             primarily responsible for adhering to the requirements of the study

        Exclusion Criteria:

          -  Have a history of hypersensitivity or allergic reaction to tizanidine or any of the
             capsule components

          -  Have dietary restrictions or food allergies that conflict with a standardized meal

          -  Have clinically significant psychiatric, gastrointestinal, pulmonary, hematologic,
             endocrine, cardiovascular, renal, or hepatic disease that requires pharmacologic
             intervention

          -  Have an ongoing seizure disorder that requires medical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Henney, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville Department of Neurology dba Kentucky Neuroscience Research Health Care Outpatient Center (HCOC)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>March 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2013</results_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>Zanaflex Capsules : 0.025 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2</title>
          <description>Zanaflex Capsules : 0.05 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3</title>
          <description>Zanaflex Capsules : 0.075 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>Dose Level 4</title>
          <description>Zanaflex Capsules : 0.1 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1</title>
          <description>Zanaflex Capsules : 0.025 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2</title>
          <description>Zanaflex Capsules : 0.05 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter AUC0–8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</title>
        <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
        <time_frame>Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Zanaflex Capsules : 0.025 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Zanaflex Capsules : 0.05 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>Zanaflex Capsules: 0.075 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 4</title>
            <description>Zanaflex Capsules: 0.1 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter AUC0–8 (Area Under the Concentration-time Curve From Time 0 to 8 Hours) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</title>
          <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
          <population>Pharmacokinetics Population</population>
          <units>hour*nanogram/mililiter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="1.79"/>
                    <measurement group_id="O2" value="6.11" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</title>
        <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
        <time_frame>Baseline and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours</time_frame>
        <population>Pharmacokinetics Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Zanaflex Capsules : 0.025 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Zanaflex Capsules : 0.05 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>Zanaflex Capsules: 0.075 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 4</title>
            <description>Zanaflex Capsules: 0.1 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter Cmax (Maximum Observed Drug Concentration in Plasma) of a Single Dose of Tizanidine at 4 Different Dose Levels in Children and Adolescents With Cerebral Palsy and Mild to Moderate Spasticity.</title>
          <description>Baseline: immediately before the standardized meal (i.e., before administration of tizanidine) on dosing day
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after administration of tizanidine
PK parameters will be derived by using WinNonlin Pro (version 5.0.1 or later, Pharsight Corp).</description>
          <population>Pharmacokinetics Population</population>
          <units>nanogram/mililiter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.60"/>
                    <measurement group_id="O2" value="5.29" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days.</time_frame>
      <desc>Treatment-emergent adverse events (TEAE) were defined as AEs with date/time of onset (or worsening) on or after the start–date/time of administration of study drug and no more than 1 day after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1</title>
          <description>Zanaflex Capsules : 0.025 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 2</title>
          <description>Zanaflex Capsules : 0.05 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert Henney, PharmD</name_or_title>
      <organization>Acorda Therapeutics, Inc.</organization>
      <phone>914-347-4300 ext 5138</phone>
      <email>hhenney@acorda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

